Objective To explore the mechanism of action of rhodopsin combined with paclitaxel in the treatment of non-small cell lung cancer(NSCLC)based on network pharmacology,and to apply experiments to verify the network pharmacology results.Methods The TCMSP,a systematic pharmacology analysis platform for traditional Chinese medicine,and the Pharmaceutical Information Query Library(PIQ),Pharmaceutical Intelligence Data(PID)were used to find out the relevant targets of rhodopsin and paclitaxel,and GeneCards,a human gene database,was used to find out the relevant disease targets of NSCLC.The STRING database and Cytoscape were used to construct the constituent-target network of rhodopsin combined with paclitaxel,and to analyze the targets,biological processes,and related pathways of rhodopsin combined with paclitaxel in the treatment of NSCLC,and at the same time,to detect the inhibitory rate of rhodopsin combined with paclitaxel on the proliferation of A549 cells using the MTT assay,and to detect the levels of core target genes obtained by ELISA for the pharmacological aspects of the network.Results The common target genes of rhodopsin combined with paclitaxel and NSCLC were 32,and the top ten target proteins obtained by PPI analysis were TP53,CASP3,TNF,EGF,PTGS2,MYC,KDR,TGFB1,MMP9,and PPARG.GO analysis and KEGG pathway analysis identified 150 biological processes and 45 relevant pathways that rhodopsin combined with paclitaxel might act on in NSCLC.MTT results showed that rhodopsin combined with paclitaxel had a significant growth inhibitory effect on A549 cells(P＜0.05),and the inhibition rate of the combined group was significantly higher than that of the rhodopsin and paclitaxel alone group(P＜0.05).ELISA results showed that the combined group of rhodopsin and paclitaxel significantly increased the CASP3 content of A549 cells(P＜0.05),and decreased TNF-α content(P＜0.05),in which the effect of the combined group was significantly better than that of the rhodopsin and paclitaxel groups(P＜0.05).Conclusion The combination of rhodopsin and paclitaxel can play a therapeutic role in NSCLC by regulating cell proliferation and apoptosis,modulating the expression of tumor suppressor genes,and inflammatory response of the relevant target pathways,and the combination of rhodopsin and paclitaxel has an inhibitory effect on the proliferation of A549 cells,and the mechanism of this may be related to the modulation of the levels of CASP3 and TNF-α.
万方数据
维普
